Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK.

JAMA Oncol. 2019 Jan 1;5(1):45-50. doi: 10.1001/jamaoncol.2018.3691.

2.

The rs4646 and rs12592697 Polymorphisms in CYP19A1 Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds.

Armamento-Villareal R, Shah VO, Aguirre LE, Meisner AL, Qualls C, Royce ME.

Front Genet. 2016 Dec 2;7:211. eCollection 2016.

3.

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12780-12785. doi: 10.1073/pnas.1615288113. Epub 2016 Oct 24.

4.

Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.

Flores KG, Steffen LE, McLouth CJ, Vicuña BE, Gammon A, Kohlmann W, Vigil L, Dayao ZR, Royce ME, Kinney AY.

J Genet Couns. 2017 Jun;26(3):480-490. doi: 10.1007/s10897-016-0001-7. Epub 2016 Aug 6.

5.

Everolimus in the Treatment of Metastatic Breast Cancer.

Royce ME, Osman D.

Breast Cancer (Auckl). 2015 Sep 6;9:73-9. doi: 10.4137/BCBCR.S29268. eCollection 2015. Review.

6.

Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides.

Lu J, Hathaway HJ, Royce ME, Prossnitz ER, Miao Y.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):725-30. doi: 10.1016/j.bmcl.2013.12.120. Epub 2014 Jan 6.

7.

Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides.

Guo H, Hathaway H, Royce ME, Prossnitz ER, Miao Y.

Bioorg Med Chem Lett. 2013 Oct 15;23(20):5484-7. doi: 10.1016/j.bmcl.2013.08.075. Epub 2013 Aug 23.

8.

The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.

Candelaria-Quintana D, Dayao ZR, Royce ME.

Breast Cancer Res Treat. 2012 Apr;132(2):355-63. doi: 10.1007/s10549-011-1800-z. Epub 2011 Oct 11. Review.

PMID:
21987034
9.

SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.

Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN.

Breast Cancer Res Treat. 2011 Nov;130(1):123-31. doi: 10.1007/s10549-011-1698-5. Epub 2011 Aug 9.

10.

Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides.

Guo H, Lu J, Hathaway H, Royce ME, Prossnitz ER, Miao Y.

Bioconjug Chem. 2011 Aug 17;22(8):1682-9. doi: 10.1021/bc200252j. Epub 2011 Jul 20.

11.

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.

Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB.

J Clin Oncol. 2011 Mar 10;29(8):1014-21. doi: 10.1200/JCO.2009.27.6543. Epub 2011 Jan 10.

12.

Method of detection and breast cancer survival disparities in Hispanic women.

Hill DA, Nibbe A, Royce ME, Wallace AM, Kang H, Wiggins CL, Rosenberg RD.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2453-60. doi: 10.1158/1055-9965.EPI-10-0164. Epub 2010 Sep 14.

13.

Bone scan demonstration of osteoblastic tumor of the breast.

Wallace AM, Rosenberg RD, Royce ME.

Surgery. 2011 Jul;150(1):135-6. doi: 10.1016/j.surg.2009.10.062. Epub 2010 Jan 4. No abstract available.

PMID:
20045544
14.

The effect of adjuvant radiotherapy on mortality differs according to primary tumor location in women with node-positive breast cancer.

Vinh-Hung V, Truong PT, Janni W, Nguyen NP, Vlastos G, Cserni G, Royce ME, Woodward WA, Promish D, Tai P, Soete G, Balmer-Majno S, Cutuli B, Storme G, Bouchardy C.

Strahlenther Onkol. 2009 Mar;185(3):161-8; discussion 169. doi: 10.1007/s00066-009-1921-z. Epub 2009 Mar 28.

PMID:
19330292
15.

Breast disease: benign and malignant.

Meisner AL, Fekrazad MH, Royce ME.

Med Clin North Am. 2008 Sep;92(5):1115-41, x. doi: 10.1016/j.mcna.2008.04.003. Review.

PMID:
18721655
16.

Idiopathic granulomatous lobular mastitis masquerading as a breast abscess and breast carcinoma.

Marriott DA, Russell J, Grebosky J, Wallace AM, Joste N, Royce ME.

Am J Clin Oncol. 2007 Oct;30(5):564-5. No abstract available.

PMID:
17921721
17.

Modeling the effect of tumor size in early breast cancer.

Verschraegen C, Vinh-Hung V, Cserni G, Gordon R, Royce ME, Vlastos G, Tai P, Storme G.

Ann Surg. 2005 Feb;241(2):309-18.

18.
19.

STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis.

Royce ME, Xia W, Sahin AA, Katayama H, Johnston DA, Hortobagyi G, Sen S, Hung MC.

Cancer. 2004 Jan 1;100(1):12-9.

20.

Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer.

Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL.

Am J Clin Oncol. 2001 Aug;24(4):421-4.

PMID:
11474279
21.

Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.

Royce ME, Hoff PM, Dumas P, Lassere Y, Lee JJ, Coyle J, Ducharme MP, De Jager R, Pazdur R.

J Clin Oncol. 2001 Mar 1;19(5):1493-500.

PMID:
11230496
22.

Colorectal cancer: chemotherapy treatment overview.

Royce ME, Medgyesy D, Zukowski TH, Dwivedy S, Hoff PM, Pazdur R.

Oncology (Williston Park). 2000 Dec;14(12 Suppl 14):40-6. Review.

23.

Novel agents for colorectal cancer.

Pazdur R, Royce ME.

Expert Opin Investig Drugs. 1999 Oct;8(10):1639-1652.

PMID:
11139816
24.

Novel oral chemotherapy agents.

Royce ME, Hoff PM, Pazdur R.

Curr Oncol Rep. 2000 Jan;2(1):31-7. Review.

PMID:
11122822
25.

Novel chemotherapy agents for colorectal cancer: oral fluoropyrimidines, oxaliplatin, and raltitrexed.

Royce ME, Hoff PM, Padzur R.

Curr Oncol Rep. 1999;1(2):161-7. Review.

PMID:
11122814
26.

Progress in colorectal cancer chemotherapy: how far have we come, how far to go?

Royce ME, Hoff PM, Pazdur R.

Drugs Aging. 2000 Sep;17(3):201-16. Review.

PMID:
11043819
27.

Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.

Royce ME, McGarry W, Bready B, Dakhil SR, Belt RJ, Goodwin JW, Gray R, Hoff PM, Winn R, Pazdur R.

J Clin Oncol. 1999 Oct;17(10):3276-82.

PMID:
10506630
28.

Fluoropyrimidines: a critical evaluation.

Brito RA, Medgyesy D, Zukowski TH, Royce ME, Ravandi-Kashani F, Hoff PM, Pazdur R.

Oncology. 1999 Jul;57 Suppl 1:2-8. Review.

PMID:
10436410
29.

Novel chemotherapeutic agents for gastrointestinal cancers.

Royce ME, Pazdur R.

Curr Opin Oncol. 1999 Jul;11(4):299-304. Review.

PMID:
10416883
30.

Phase II trial of docetaxel for cholangiocarcinoma.

Pazdur R, Royce ME, Rodriguez GI, Rinaldi DA, Patt YZ, Hoff PM, Burris HA.

Am J Clin Oncol. 1999 Feb;22(1):78-81.

PMID:
10025387
31.

Identification of DNA sequences required for mouse APRT gene expression.

Dush MK, Briggs MR, Royce ME, Schaff DA, Khan SA, Tischfield JA, Stambrook PJ.

Nucleic Acids Res. 1988 Sep 12;16(17):8509-24.

Supplemental Content

Loading ...
Support Center